Cited by 22Medical Imaging Techniques and ApplicationsRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment

A VISION Substudy of Reader Agreement on 68 Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177 Lu-PSMA-617 Radioligand Therapy

Open access
Kuo, Phillip H., Yoo, Don C., Avery, Ryan, Seltzer, Marc, Calais, Jeremie, Nagarajah, James, Weber, Wolfgang A., Fendler, Wolfgang P. +8 more·2023·Journal of Nuclear Medicine

Abstract

68Ga-gozetotide (68Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, 68Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with 177Lu-vipivotide tetraxetan (177Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of 68Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, 68Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50–0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38–0.71), 0.67 (95% CI, 0.52–0.83), and 0.59 (95% CI, 0.43–0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49–0.99), 0.76 (95% CI, 0.46–0.99), and 0.89 (95% CI, 0.67–0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66–0.85) for reader 1, 70 of 88 (0.80; 0.70–0.87) for reader 2, and 73 of 96 (0.76; 0.66–0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for 68Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.122.265077

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 16 · Cited by 22

Authors
Kuo, P. H., Yoo, D. C., Avery, R., Seltzer, M., Calais, J., Nagarajah, J., Weber, W. A., Fendler, W. P., Hofman, M. S., Krause, B. J., Brackman, M., Kpamegan, E., Ghebremariam, S., Benson, T., Catafau, A. M., & Kendi, A. T.
Affiliations
  • University of Arizona (US)
  • Brown University (US)
  • Northwestern University (US)
  • Dartmouth College (US)
  • Radboud University Medical Center (NL)
  • Technical University of Munich (DE)
  • Essen University Hospital (DE)
  • The University of Melbourne (AU)
  • Universitätsmedizin Rostock (DE)
  • Novartis (United States) (US)
  • Mayo Clinic (US)
Corresponding author
Kuo, Phillip H.
Venue
Journal of Nuclear Medicine
Published
2023-05-25
Volume
64
Issue
8
Pages
1259-1265
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W4378214169
Cited by
22
References
16
Citations by year
2026: 5 · 2025: 5 · 2024: 10 · 2023: 2
FWCI
3.63
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Nuclear Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Funders
  • Amgen
  • AstraZeneca
  • Bayer
  • Sanofi
  • Advanced Accelerator Applications
  • Eisai
  • Astellas Pharma
  • Ipsen
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
Keywords
68Ga-PSMA-11 PET/CT, 177Lu-PSMA-617, radioligand therapy, castration-resistant prostate cancer, metastatic prostate cancer, inter-reader variability, patient eligibility, visual interpretation, reader agreement, Fleiss' kappa
MeSH terms
Positron Emission Tomography Computed Tomography, Dipeptides, Gallium Isotopes, Gallium Radioisotopes, Heterocyclic Compounds, 1-Ring, Humans, Male, Prostatic Neoplasms, Retrospective Studies, Reproducibility of Results, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review